HUP9602122A3 - Camptothecin derivatives, process for the preparation thereof and pharmaceutical compositions containing them - Google Patents
Camptothecin derivatives, process for the preparation thereof and pharmaceutical compositions containing themInfo
- Publication number
- HUP9602122A3 HUP9602122A3 HU9602122A HUP9602122A HUP9602122A3 HU P9602122 A3 HUP9602122 A3 HU P9602122A3 HU 9602122 A HU9602122 A HU 9602122A HU P9602122 A HUP9602122 A HU P9602122A HU P9602122 A3 HUP9602122 A3 HU P9602122A3
- Authority
- HU
- Hungary
- Prior art keywords
- preparation
- pharmaceutical compositions
- compositions containing
- camptothecin derivatives
- camptothecin
- Prior art date
Links
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19739195 | 1995-08-02 | ||
| JP34061995 | 1995-12-27 | ||
| JP17337296 | 1996-07-03 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HU9602122D0 HU9602122D0 (en) | 1996-09-30 |
| HUP9602122A2 HUP9602122A2 (en) | 1997-11-28 |
| HUP9602122A3 true HUP9602122A3 (en) | 1998-07-28 |
Family
ID=27323772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9602122A HUP9602122A3 (en) | 1995-08-02 | 1996-08-01 | Camptothecin derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5837673A (hu) |
| EP (1) | EP0757049B1 (hu) |
| KR (1) | KR100387191B1 (hu) |
| CN (2) | CN1143859C (hu) |
| AT (1) | ATE178067T1 (hu) |
| AU (1) | AU717653B2 (hu) |
| BG (1) | BG63342B1 (hu) |
| CA (1) | CA2182244C (hu) |
| DE (1) | DE69601841T2 (hu) |
| DK (1) | DK0757049T3 (hu) |
| ES (1) | ES2131913T3 (hu) |
| GR (1) | GR3029796T3 (hu) |
| HK (1) | HK1005545A1 (hu) |
| HU (1) | HUP9602122A3 (hu) |
| IL (1) | IL118957A (hu) |
| MY (1) | MY116665A (hu) |
| NO (1) | NO315469B1 (hu) |
| RU (1) | RU2138503C1 (hu) |
| SG (1) | SG50747A1 (hu) |
| TW (1) | TW466242B (hu) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2192725C (en) | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
| US6096336A (en) * | 1996-01-30 | 2000-08-01 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| TW527183B (en) * | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| TW409058B (en) * | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
| WO1998014459A1 (de) * | 1996-09-30 | 1998-04-09 | Bayer Aktiengesellschaft | Glycokonjugate von modifizierten camptothecin-derivaten (20-o-verknüpfung) |
| DE19640207A1 (de) * | 1996-09-30 | 1998-04-02 | Bayer Ag | Glycokonjugate von modifizierten Camptothecin-Derivaten (A- oder B-Ring-Verknüpfung) |
| TW464652B (en) * | 1996-10-30 | 2001-11-21 | Tanabe Seiyaku Co | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof |
| US6361938B1 (en) * | 1996-11-08 | 2002-03-26 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
| ID23424A (id) * | 1997-05-14 | 2000-04-20 | Bayer Ag | Glikokonjugat dari 20(s)-kamptotesin |
| US6011042A (en) * | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
| US6228855B1 (en) | 1999-08-03 | 2001-05-08 | The Stehlin Foundation For Cancer Research | Aromatic esters of camptothecins and methods to treat cancers |
| US6352996B1 (en) | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| EP1229934B1 (en) | 1999-10-01 | 2014-03-05 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| US20030054977A1 (en) * | 1999-10-12 | 2003-03-20 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
| US20040009229A1 (en) * | 2000-01-05 | 2004-01-15 | Unger Evan Charles | Stabilized nanoparticle formulations of camptotheca derivatives |
| US20020077290A1 (en) * | 2000-03-17 | 2002-06-20 | Rama Bhatt | Polyglutamic acid-camptothecin conjugates and methods of preparation |
| WO2002000734A1 (fr) * | 2000-06-29 | 2002-01-03 | Daiichi Pharmaceutical Co., Ltd. | Compose dds et son procede de preparation |
| MXPA03004095A (es) | 2000-11-09 | 2004-09-10 | Neopharm Inc | Complejos de sn-38 con lipidos y sus metodos de uso. |
| WO2003030864A1 (en) | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
| TWI313609B (en) * | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
| US20030092608A1 (en) * | 2001-08-21 | 2003-05-15 | Takayuki Kawaguchi | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
| WO2003033525A1 (en) * | 2001-10-12 | 2003-04-24 | Debio Recherche Pharmacuetique S.A. | Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament |
| TW200306314A (en) * | 2002-04-16 | 2003-11-16 | Tanabe Seiyaku Co | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation |
| JP4745664B2 (ja) * | 2002-10-31 | 2011-08-10 | 日本化薬株式会社 | カンプトテシン類の高分子誘導体 |
| WO2004092205A1 (en) * | 2003-04-16 | 2004-10-28 | Debio Recherche Pharmacuetique S.A. | Hydroxy-substituted-20-acyloxy-camptothecin polymer derivatives and use of the same for the manufacture of a medicament |
| US20040247624A1 (en) * | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| WO2005028539A2 (en) * | 2003-09-17 | 2005-03-31 | Nektar Therapeutics Al, Corporation | Multi-arm polymer prodrugs |
| US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| JP4433918B2 (ja) * | 2004-07-15 | 2010-03-17 | コニカミノルタエムジー株式会社 | 画像形成方法 |
| PL1792927T3 (pl) | 2004-09-22 | 2013-09-30 | Nippon Kayaku Kk | Nowy kopolimer blokowy, preparat micelarny i lek przeciwnowotworowy zawierający ten preparat micelarny jako składnik czynny |
| KR100651728B1 (ko) * | 2004-11-10 | 2006-12-06 | 한국전자통신연구원 | 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법 |
| TWI375678B (en) | 2005-06-09 | 2012-11-01 | Yakult Honsha Kk | A method of preparation of a tricyclic ketone |
| ITFI20050246A1 (it) * | 2005-12-02 | 2007-06-03 | Menarini Internat Operations Luxembourg Sa | Uso di un composto comprendente un derivato della camptotecina per la preparazione di formulazioni farmaceutiche utili nel trattamento del melanoma |
| US7671067B2 (en) | 2006-02-09 | 2010-03-02 | Enzon Pharmaceuticals, Inc. | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
| US7462627B2 (en) | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| WO2007111211A1 (ja) | 2006-03-28 | 2007-10-04 | Nippon Kayaku Kabushiki Kaisha | タキサン類の高分子結合体 |
| CA2652656A1 (en) | 2006-05-18 | 2007-11-29 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
| JP5503872B2 (ja) | 2006-11-06 | 2014-05-28 | 日本化薬株式会社 | 核酸系代謝拮抗剤の高分子誘導体 |
| EP2090607B1 (en) | 2006-11-08 | 2015-05-20 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
| WO2008066902A2 (en) | 2006-11-30 | 2008-06-05 | Nektar Therapeutics Al, Corporation | Method for preparing a polymer conjugate |
| KR20090108082A (ko) | 2007-02-09 | 2009-10-14 | 엔존 파마슈티컬즈, 인코포레이티드 | 7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법 |
| USRE46190E1 (en) | 2007-09-28 | 2016-11-01 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
| CN101977631A (zh) | 2008-03-18 | 2011-02-16 | 日本化药株式会社 | 生理活性物质的高分子量偶联物 |
| BRPI0910746B8 (pt) * | 2008-04-30 | 2021-05-25 | Immunogen Inc | agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica |
| JP5366940B2 (ja) | 2008-05-08 | 2013-12-11 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
| WO2010019233A1 (en) | 2008-08-11 | 2010-02-18 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
| HUE047352T2 (hu) | 2008-09-23 | 2020-04-28 | Nektar Therapeutics | Eljárás ütemezett beadásra kamptotecin elõgyógyszerekkel (például PEG-ironotekánnal) |
| JP5544357B2 (ja) | 2009-05-15 | 2014-07-09 | 日本化薬株式会社 | 水酸基を有する生理活性物質の高分子結合体 |
| CN103221054A (zh) | 2010-11-17 | 2013-07-24 | 日本化药株式会社 | 新的胞苷类代谢拮抗剂的高分子衍生物 |
| WO2012088445A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| JP5860480B2 (ja) | 2011-01-11 | 2016-02-16 | キャプシュゲル・ベルジウム・エヌ・ヴィ | プルランを含む新しい硬カプセル |
| RU2623426C2 (ru) | 2011-09-11 | 2017-06-26 | Ниппон Каяку Кабусики Кайся | Способ получения блок-сополимера |
| KR102320907B1 (ko) | 2012-10-11 | 2021-11-02 | 다이이찌 산쿄 가부시키가이샤 | 글리신아미드 화합물의 제조 방법 |
| ES2782248T3 (es) | 2012-10-19 | 2020-09-11 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila |
| WO2015098099A1 (ja) | 2013-12-25 | 2015-07-02 | 第一三共株式会社 | 抗ｔｒｏｐ２抗体－薬物コンジュゲート |
| BR112016013482B1 (pt) | 2014-01-31 | 2022-04-19 | Daiichi Sankyo Company, Limited | Conjugado de anticorpo anti-her2-fármaco, fármacos antitumor e/ou anticâncer e composição farmacêutica |
| NZ722668A (en) | 2014-04-10 | 2024-02-23 | Daiichi Sankyo Europe Gmbh | Anti-her3 antibody-drug conjugate |
| WO2015155976A1 (ja) | 2014-04-10 | 2015-10-15 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| CN107922477B (zh) | 2015-06-29 | 2022-11-01 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| WO2018110515A1 (ja) | 2016-12-12 | 2018-06-21 | 第一三共株式会社 | 抗体－薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ |
| KR102537651B1 (ko) | 2017-01-17 | 2023-05-26 | 다이이찌 산쿄 가부시키가이샤 | 항 gpr20 항체 및 항 gpr20 항체-약물 콘쥬게이트 |
| BR112019021391A2 (pt) | 2017-04-14 | 2020-05-05 | Capsugel Belgium Nv | cápsulas de pululano |
| WO2018189587A1 (en) | 2017-04-14 | 2018-10-18 | Capsugel Belgium Nv | Process for making pullulan |
| TW202330036A (zh) | 2017-05-15 | 2023-08-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
| SG11202001514XA (en) | 2017-08-31 | 2020-03-30 | Daiichi Sankyo Co Ltd | Novel method for producing antibody-drug conjugate |
| EP3677589A4 (en) | 2017-08-31 | 2021-04-21 | Daiichi Sankyo Company, Limited | IMPROVED PROCESS FOR PREPARING ANTIBODY-ACTIVE CONJUGATE |
| AU2019270457A1 (en) | 2018-05-18 | 2020-12-03 | Glycotope Gmbh | Anti-MUC1 antibody |
| WO2024020734A1 (en) * | 2022-07-25 | 2024-02-01 | Immunogen, Inc. | Novel processes for preparing camptothecin derivatives |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3682874D1 (de) | 1985-10-21 | 1992-01-23 | Daiichi Seiyaku Co | Pyranoindolizinderivate und verfahren zu ihrer herstellung. |
| US4981968A (en) * | 1987-03-31 | 1991-01-01 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
| US5244903A (en) * | 1987-03-31 | 1993-09-14 | Research Triangle Institute | Camptothecin analogs as potent inhibitors of topoisomerase I |
| US5049668A (en) * | 1989-09-15 | 1991-09-17 | Research Triangle Institute | 10,11-methylenedioxy-20(RS)-camptothecin analogs |
| JP2540357B2 (ja) * | 1987-06-24 | 1996-10-02 | 第一製薬株式会社 | 六環性化合物 |
| US4939255A (en) * | 1987-06-24 | 1990-07-03 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic camptothecin derivatives |
| ATE211142T1 (de) * | 1989-09-15 | 2002-01-15 | Res Triangle Inst | Verfahren zur herstellung von 10,11-methylendioxy-20(rs)-camptothecin und 10,11-methylendioxy-20(s)-camptothecin-analog |
| WO1991004260A2 (en) * | 1989-09-15 | 1991-04-04 | Research Triangle Institute | 10,11-methylenedioxy-20(rs)-camptothecin and 10,11-methylenedioxy-20(s)-camptothecin analogs |
| US5140010A (en) * | 1989-09-28 | 1992-08-18 | Immunobiology Research Institute | Stabilized aqueous formulations of thymopentin |
| EP0544000B1 (en) * | 1990-08-17 | 1997-05-02 | Drug Delivery System Institute, Ltd. | N-acetylcarboxymethylchitosan derivative and production thereof |
| DE69209969T2 (de) * | 1991-10-29 | 1996-09-12 | Glaxo Wellcome Inc | Wasserlösliche Camptothecinderivate |
| JPH06228141A (ja) * | 1992-01-24 | 1994-08-16 | Takeda Chem Ind Ltd | 縮合複素環誘導体、その塩、その製造法および用途 |
| EP0556585A3 (en) * | 1992-01-24 | 1993-09-01 | Takeda Chemical Industries, Ltd. | Condensed camptothecin derivatives their production and use as antitumor agents |
| WO1993016698A1 (en) * | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | SUBSTITUTED FURO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLINONES |
| JP3359955B2 (ja) * | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
| DE4236237A1 (de) * | 1992-10-27 | 1994-04-28 | Behringwerke Ag | Prodrugs, ihre Herstellung und Verwendung als Arzneimittel |
| CA2134348C (en) * | 1993-02-26 | 2007-01-02 | Hideo Nogusa | Polysaccharide derivatives and drug carriers |
| GB9320781D0 (en) * | 1993-10-08 | 1993-12-01 | Erba Carlo Spa | Polymer-bound camptothecin derivatives |
-
1996
- 1996-07-24 SG SG1996010359A patent/SG50747A1/en unknown
- 1996-07-25 AU AU60698/96A patent/AU717653B2/en not_active Ceased
- 1996-07-25 IL IL11895796A patent/IL118957A/xx not_active IP Right Cessation
- 1996-07-29 CA CA002182244A patent/CA2182244C/en not_active Expired - Fee Related
- 1996-07-30 EP EP96305579A patent/EP0757049B1/en not_active Expired - Lifetime
- 1996-07-30 DK DK96305579T patent/DK0757049T3/da active
- 1996-07-30 AT AT96305579T patent/ATE178067T1/de not_active IP Right Cessation
- 1996-07-30 US US08/689,018 patent/US5837673A/en not_active Expired - Lifetime
- 1996-07-30 ES ES96305579T patent/ES2131913T3/es not_active Expired - Lifetime
- 1996-07-30 DE DE69601841T patent/DE69601841T2/de not_active Expired - Fee Related
- 1996-07-31 BG BG100758A patent/BG63342B1/bg unknown
- 1996-08-01 NO NO19963214A patent/NO315469B1/no not_active IP Right Cessation
- 1996-08-01 MY MYPI96003153A patent/MY116665A/en unknown
- 1996-08-01 HU HU9602122A patent/HUP9602122A3/hu unknown
- 1996-08-01 RU RU96115394A patent/RU2138503C1/ru not_active IP Right Cessation
- 1996-08-02 CN CNB001326619A patent/CN1143859C/zh not_active Expired - Fee Related
- 1996-08-02 TW TW085109331A patent/TW466242B/zh not_active IP Right Cessation
- 1996-08-02 CN CN96106979A patent/CN1075501C/zh not_active Expired - Fee Related
- 1996-08-02 KR KR1019960032296A patent/KR100387191B1/ko not_active IP Right Cessation
-
1998
- 1998-05-29 HK HK98104671A patent/HK1005545A1/xx not_active IP Right Cessation
-
1999
- 1999-03-26 GR GR990400802T patent/GR3029796T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL118957A0 (en) | 1996-10-31 |
| AU717653B2 (en) | 2000-03-30 |
| NO963214L (no) | 1997-02-03 |
| KR19980013708A (ko) | 1998-05-15 |
| CN1308078A (zh) | 2001-08-15 |
| RU2138503C1 (ru) | 1999-09-27 |
| SG50747A1 (en) | 1998-07-20 |
| HU9602122D0 (en) | 1996-09-30 |
| HK1005545A1 (en) | 1999-01-15 |
| CN1075501C (zh) | 2001-11-28 |
| MY116665A (en) | 2004-03-31 |
| EP0757049B1 (en) | 1999-03-24 |
| DK0757049T3 (da) | 1999-06-23 |
| ES2131913T3 (es) | 1999-08-01 |
| KR100387191B1 (ko) | 2003-10-04 |
| CN1143859C (zh) | 2004-03-31 |
| HUP9602122A2 (en) | 1997-11-28 |
| ATE178067T1 (de) | 1999-04-15 |
| NO963214D0 (no) | 1996-08-01 |
| BG100758A (bg) | 1997-02-28 |
| CN1145365A (zh) | 1997-03-19 |
| BG63342B1 (bg) | 2001-10-31 |
| NO315469B1 (no) | 2003-09-08 |
| IL118957A (en) | 2000-11-21 |
| CA2182244C (en) | 2004-02-03 |
| TW466242B (en) | 2001-12-01 |
| DE69601841T2 (de) | 1999-08-05 |
| US5837673A (en) | 1998-11-17 |
| CA2182244A1 (en) | 1997-02-03 |
| GR3029796T3 (en) | 1999-06-30 |
| EP0757049A1 (en) | 1997-02-05 |
| AU6069896A (en) | 1997-02-06 |
| DE69601841D1 (de) | 1999-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9602122A3 (en) | Camptothecin derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
| HUP9603495A2 (en) | 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-compounds, pharmaceutical compositions containing the same and process for their preparation | |
| HUP9603494A3 (en) | Hydroxycarboxamide derivatives, pharmaceutical compositions containing them, process for the preparation thereof | |
| HUP9900974A3 (en) | Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them | |
| HUP9700358A3 (en) | New oxazolidinon derivatives, process for their preparation and pharmaceutical compositions containing them | |
| IL117598A (en) | Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP9904680A3 (en) | Thienopyrimidine derivatives, pharmaceutical compositions containing them and process for their preparation | |
| HUP0001508A3 (en) | 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them | |
| ZA968945B (en) | 1,3-Dihydro-indol-2-one derivatives process for their preparation and the pharmaceutical compositions containing them | |
| HUP9802565A3 (en) | N-benzyl-dioxothiazolidinylmethyl-benzamide derivatives, pharmaceutical compositions containing them and process for producing the same | |
| AU4821096A (en) | Benzazepine-, benzoxazepine- and benzothiazepine-N-acetic derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP9802200A3 (en) | Rapamycin derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP9901086A3 (en) | Arylsulfonylaminobenzene derivatives, pharmaceutical compositions containing them and their use for producing pharmaceutical compositions | |
| HUP0001555A3 (en) | Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation | |
| HUP9800138A3 (en) | 8-substituted-1,3,8-triaza-spiro [4,5]-decan-4-on derivatives, process for producing them, pharmaceutical compositions containing the same and their use | |
| AU6362796A (en) | Substituted 4-phenylaminothiazoles, their process for preparation and the pharmaceutical compositions containing them | |
| HUP9702400A3 (en) | Substituted camptothecin derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP9602635A2 (en) | 4-aciloxy-benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP9901739A3 (en) | Aminoisoquinolines and aminothienopyridine derivatives, process for producing thereof and pharmaceutical compositions containing them | |
| IL113103A0 (en) | Piperidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
| HUP9901485A2 (en) | Heterocyclylcarboxamide derivatives, pharmaceutical compositions containing the same, process for their preparation and their use | |
| HUP9801386A3 (en) | Indazolecarboxamide derivatives, preparation thereof and pharmaceutical compositions containing them | |
| GB9617893D0 (en) | New pharmaceutical derivatives, process for obtaining them and pharmaceutical compositions containing them | |
| IL141954A0 (en) | Benzothiazolone derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP0003174A3 (en) | 20(s) camptothecin glycoconjugates, process for their preparation and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB9A | Succession in title |
Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP Free format text: FORMER OWNER(S): TANABE SEIYAKU CO. LTD., JP |
|
| FD9A | Lapse of provisional protection due to non-payment of fees |